The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

Atherosclerosis. 2007 Aug;193(2):445-8. doi: 10.1016/j.atherosclerosis.2006.08.039. Epub 2006 Sep 20.

Abstract

Objective: Missense mutations in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) can cause familial hypercholesterolemia. However, two nonsense variants of PCSK9, Y142X and C679X, found in approximately 2% of black American subjects, are associated with a 28% reduction in mean low density lipoprotein (LDL)-cholesterol. We sought to determine the frequency and effect of these nonsense variants in an African population.

Methods and results: PCSK9 genotypes were determined in 653 black African women attending two antenatal clinics in Zimbabwe. C679X occurred in 3.7% of subjects and was associated with a 27% reduction in LDL-cholesterol (1.6+/-0.3 mmol/L versus 2.2+/-0.7 mmol/L in non-carriers). We did not observe the Y142X variant.

Conclusions: Our results show that the PCSK9 C679X variant has a marked cholesterol-lowering effect.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cholesterol, LDL / blood*
  • Cholesterol, LDL / genetics
  • Codon, Nonsense
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / genetics
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases / genetics*
  • Zimbabwe

Substances

  • Cholesterol, LDL
  • Codon, Nonsense
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases